Advertisement

Place de la chimiothérapie dans le traitement des tumeurs de l’ovaire à la limite de la malignité

  • C. Lhommé
  • P. Pautier
  • P. Morice
  • D. Castaigne
  • C. Pomel
  • A. Rey
  • C. Balleyguier
  • C. Haie-Meder
  • P. Duvillard
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Tropé C, Kaern J (1998) Management of borderline tumors of the ovary: State of the art. Semin Oncol, 25: 372–80PubMedGoogle Scholar
  2. 2.
    Elchalal U, Dgani R, Piura B et al. (1995) Current concepts in management of epithelial ovarian tumors of low malignant potential. Obstet Gynecol Surv 50(1): 62–70CrossRefPubMedGoogle Scholar
  3. 3.
    Kaern J, Tropé CG, Abeler VM (1993) A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 71(5): 1810–20PubMedGoogle Scholar
  4. 4.
    Burger CW, Prinssen HM, Baak JPA et al. (2000) The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer 10: 181–97CrossRefPubMedGoogle Scholar
  5. 5.
    Tamakoshi K, Kikkawa F, Nakashima N et al. (1997) Clinical behaviour of borderline ovarian tumors: A Study of 150 cases. J Surg Oncol 64: 147–52CrossRefPubMedGoogle Scholar
  6. 6.
    Zanetta G, Rota S, Chiari S et al. (2001). Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19(10): 2658–64PubMedGoogle Scholar
  7. 7.
    Leake J, Currie J, Rosenshein N et al. (1992) Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 47: 150–8CrossRefPubMedGoogle Scholar
  8. 8.
    Chambers JT (1989) Borderline ovarian tumors: a review of treatment. Yale J. Biol. Med., 62: 351–65PubMedGoogle Scholar
  9. 9.
    Tropé C, Kaern J, Vergote IB et al. (1993) Are borderline tumors of the ovary overtreated TOLMh surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 51: 236–43CrossRefPubMedGoogle Scholar
  10. 10.
    Kurman RJ, Trimble CL (1993) The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12: 120–7PubMedGoogle Scholar
  11. 11.
    Tropé CG, Kristensen G, Makar A (2000) Surgery for borderline tumor of the ovary. Semin Surg Oncol 19(1): 69–75CrossRefPubMedGoogle Scholar
  12. 12.
    Lim-Tan S, Cajigas H, Scully R (1988) Ovarian cystectomy for serous borderline. tumors: a follow-up study of 35 cases. Obstet Gynecol 72: 775–80PubMedGoogle Scholar
  13. 13.
    Darai E, Teboul J, Fauconnier A (1998 a) Management and outcome of borderline ovarian tumors indicentally discovered at or after laparoscopy. Acta Obstet Gynecol Scand 77: 451–7CrossRefPubMedGoogle Scholar
  14. 14.
    Morice P, Camatte S, El Hassan J et al. (2001) Clinical outcomes and fertility results after conservative treatment for ovarian borderline tumor. Fertil Steril 75: 92–6CrossRefPubMedGoogle Scholar
  15. 15.
    Gershenson D, Silva E, Levy L (1998 a) Ovarian Serous Borderline Tumors with Invasive Peritoneal Implants. Cancer 82: 1096–103CrossRefPubMedGoogle Scholar
  16. 16.
    Gershenson D, Silva EL, Tortolero-Luna G (1998 b) Serous Borderline Tumors of the Ovary with Non invasive Peritoneal Implants. Cancer 83: 2157–63CrossRefPubMedGoogle Scholar
  17. 17.
    Morice S, Camatte A, Rey D et al. (2002) Prognostic factors of patients with advanced stage serous borderline tumors of the ovary. Ann Oncol 14: 592–8Google Scholar
  18. 18.
    Piura B, Dgani R, Blickstein et al. (1992) Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. Int J Gynecol Cancer 2: 189–95CrossRefPubMedGoogle Scholar
  19. 19.
    Hsu YK, Parmely TH, Rosenhein NB et al. (1987) Neoplastic and nonneoplas-tic.mesothelioma proliferations in ovarian tumors of low malignant potential. Obstet Gynecol 770: 923–31Google Scholar
  20. 20.
    Crispens MA, Bodurka D, Deavers M et al. (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99(1): 3–10CrossRefPubMedGoogle Scholar
  21. 21.
    Camatte S, Morice P, Pautier P et al. (2002) Fertility results after conservative treatment of advanced stage serous borderline tumors of the ovary. BJOG 109: 376–80PubMedGoogle Scholar
  22. 22.
    Bell DA, Weinstock RA, Scully R (1988) Peritoneal implants of ovarian serous borderline tumors:histologic features and prognosis. Cancer 62: 2212–22PubMedGoogle Scholar
  23. 23.
    Seidman J, Kurman R (1996) Subclassification of serous borderline tumors of the ovary into begnin and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20: 1331–45PubMedGoogle Scholar
  24. 24.
    Casey AC, Bell DA, Lage JM et al. (1993) Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 50: 316–22CrossRefPubMedGoogle Scholar
  25. 25.
    Parker RL, Clement PB, Chercover DJ et al. (2004) Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int J Gynecol Pathol 23(3): 265–72PubMedGoogle Scholar
  26. 26.
    Morice P, Thoury A, Sabourin JC et al. (2003) Spontaneous regression of peritoneal implants in borderline ovarian tumor after salpingo-oophorectomy. J Clin Oncol 21: 3536–8CrossRefPubMedGoogle Scholar
  27. 27.
    Taylor HC, Alson WE (1932) Spontaneous regression of peritoneal implantations from ovarian papillary cystadenoma. Am J Cancer 16: 1305–25Google Scholar
  28. 28.
    Trimble CL, Kosary C, Trimble EL (2002) Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86: 34–7CrossRefPubMedGoogle Scholar
  29. 29.
    Gersherson DM, Silva EG (1990) Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 65: 578–85Google Scholar
  30. 30.
    Michael H, Sutton G, Roth L (1987) Ovarian carcinoma with extracellular mucin production: reassessment of « pseudomyxoma ovarii et peritonei ». Int J Gynecol Pathol 6: 298–310PubMedGoogle Scholar
  31. 31.
    Leake JF, Ader JS, Woodruff JD (1991) Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 42: 124–30CrossRefPubMedGoogle Scholar
  32. 32.
    Tan LK, Flynn SD, Carcangiu ML (1994) Ovarian serous borderline tumors with lymph node involvement: clinicopathologic and DNA content study of seven cases and review of the litterature. Am J Surg Pathol 18: 904–12PubMedGoogle Scholar
  33. 33.
    Camatte S, Morice P, Atallah D et al. (2002) Lymph node disorders and prognostic value of nodal involvement in patients treated for borderline ovarian tumor: An analysis of a series of 42 lymphadénectomies. J Am Coll Surg 195: 332–8CrossRefPubMedGoogle Scholar
  34. 34.
    Yoonesi M, Crickard K, Celik C et al. (1988). Borderline epithelial tumors of the ovary: ovarian intraepithelial neoplasia. Obstet Gynecol Survey 43(8): 435–44Google Scholar
  35. 35.
    Michel G, Rochard F, Prade M et al. (1994) Incidence and prognosis of intraoperative rupture of borderline ovarian tumours. In: Bruhat MA The management of adnexal cysts. Blackwell, Oxford, pp 116–21Google Scholar
  36. 36.
    Kennedy AW, Hart WR (1996) Ovarian papillary serous tumors of low malignant poten-tial (serous borderline tumors). A long term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 78: 278–86CrossRefPubMedGoogle Scholar
  37. 37.
    Beller U, Bigelow B, Beckman EM et al. (1983) Epithelial carcinoma of the ovary in the reproductive years: clinical and morphological characterization. Gynecol Oncol 15: 422–6CrossRefPubMedGoogle Scholar
  38. 38.
    Tavasolli FA (1988) Serous tumor of low malignant potential with early stromal invasion (serous LMP with micro-invasion). Mod Pathol 1: 407–13Google Scholar
  39. 39.
    Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 22(12): 1449–62CrossRefPubMedGoogle Scholar
  40. 40.
    Darai E, Walker-Combrouze F, Mlika-Cabanne N et al. (1998 b) Expression of p53 protien in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases. Eur J Gynecol Oncol 19: 144–9Google Scholar
  41. 41.
    Eltabbakh GH, Belinson JL, Kennedy AW et al. (1997) P53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 65: 218–242CrossRefPubMedGoogle Scholar
  42. 42.
    Gershenson D, Deavers M, Diaz S et al. (1999) Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5: 4053–8PubMedGoogle Scholar
  43. 43.
    Friedlander ML, Hedley DW, Swanson C et al. (1988) Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. Clin Oncol 6(2): 282-90Google Scholar
  44. 44.
    De Nictolis M, Montironi R, Tommasoni S et al. (1992) Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 70:152–60PubMedGoogle Scholar
  45. 45.
    McCaughey WT, Kirk ME, Lester W (1984) Peritoneal epithelial lesions associated with proliferative serous tumours of ovary. Histopathology 8:195–208PubMedGoogle Scholar
  46. 46.
    Michael H, Roth LM (1986) Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 57:1240–7PubMedGoogle Scholar
  47. 47.
    Gershenson DM (2002) Is micropapillary serous carcinoma for real? Cancer 15: 95(4): 677-80. Comment on: Cancer 2002 Aug 15; 95(4): 791-800Google Scholar
  48. 48.
    Piura B, Rabinovich A, Yanai-Inbar I (2000) Micropapillary serous carcinoma of the ovary: case report and review of literature. Eur J Gynaecol Oncol 21(4): 374–6PubMedGoogle Scholar
  49. 49.
    Young RC, Walton LA, Ellenberg SS et al. (1990) Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322: 1021–7PubMedGoogle Scholar
  50. 50.
    Creasman WT, Park R, Norris H et al. (1982) Stage I borderline ovarian tumors. Obstet Gynecol 59: 93–6PubMedGoogle Scholar
  51. 51.
    Lackman F, Carey MS, Kirk ME et al. (2003) Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol 90(2): 407–12CrossRefPubMedGoogle Scholar
  52. 52.
    Prat J (1999) Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Adv Anat Pathol 6(5): 247–74PubMedGoogle Scholar
  53. 53.
    Yazigi R, Munoz AK, Sandstad J et al. (1991) Cisplatin-based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential. Eur J Gynecol Oncol 12(6): 451–5Google Scholar
  54. 54.
    Sutton GP, Bundy BN, Omura GA et al. (1991) Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gyn Oncol 41: 230–3CrossRefGoogle Scholar
  55. 55.
    Eltabbakh GH, Srivastava A, Garafano LL (2000) Surgical response of advanced-stage borderline ovarian tumors to paclitaxel and cisplatin chemotherapy. Gynecol Oncol 77: 343–4CrossRefPubMedGoogle Scholar
  56. 56.
    Bostwick DG, Tazelaar HD, Ballon SC et al. (1986) Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 58: 2052–65PubMedGoogle Scholar
  57. 57.
    Barnhill D, Heller P, Brzozowski P et al. (1985) Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 65(1): 53–9PubMedGoogle Scholar
  58. 58.
    Kliman L, Rome RM, Fortune DW (1986) Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 68: 338–44PubMedGoogle Scholar
  59. 59.
    Nation JG, Krepart GV (1986) Ovarian carcinoma of low malignant potential: Staging and treatment. Am J Obstet Gynecol 154: 290–3PubMedGoogle Scholar
  60. 60.
    O’Quinn AG, Hannigan EV (1985) Epithelial ovarian neoplasms of low malignant potential. Gynecol Oncol 21: 177–85Google Scholar
  61. 61.
    Barakat RR, Benjamin I, Lewis JL Jr et al. (1995) Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 59: 390–3CrossRefPubMedGoogle Scholar
  62. 62.
    Fort MG, Pierce VK, Saigo PE et al. (1989) Evidence of the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 32: 269–72CrossRefPubMedGoogle Scholar
  63. 63.
    Benjamin I, Barakat R, Hakes T et al. (1994) Platinum-based chemotherapy for advanced stage ovarian serous carcinoma of low malignant potential. Proc Ann Meet Am Soc Clin Oncol 13: Abstract no 834Google Scholar
  64. 64.
    Barnhill D, Kurman RJ, Brady MF et al. (1995) Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 13(11): 2752–6PubMedGoogle Scholar
  65. 65.
    Elias D, Sabourin JC (1999) FrPseudomyxome péritonéal. Revue de la littérature. J Chir 136: 341–7Google Scholar
  66. 66.
    Wertheim I, Fleischhaker D, McLachlin CM et al. (1994) Pseudomyxoma peritonei: a review of 23 cases. Obstet Gynecol 84(1): 17–21PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • C. Lhommé
  • P. Pautier
  • P. Morice
  • D. Castaigne
  • C. Pomel
  • A. Rey
  • C. Balleyguier
  • C. Haie-Meder
  • P. Duvillard

There are no affiliations available

Personalised recommendations